In a nutshell This study compared the effectiveness of three low-intensity chemotherapy combinations to treat patients with classical Hodgkin lymphoma (HL) following stem cell transplantation (SCT). There were no significant differences between the three chemotherapy types in terms of patients’ survival and relapse. Some background...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Tucatinib in combination with trastuzumab and capecitabine for HER2 positive metastatic breast cancer
In a nutshell This study aimed to investigate the safety and effectiveness of tucatinib in combination with trastuzumab and capecitabine in patients with HER2 positive metastatic breast cancer who have had disease progression with other treatments. This study concluded that this treatment combination was safe and...
Read MoreHave the outcomes of stem cell transplants for young patients with relapsed or refractory Hodgkin lymphoma improved over time?
In a nutshell This study examined if the outcomes of stem cell transplants (SCT) have improved for young patients with relapsed or refractory Hodgkin lymphoma (HL) over time. The results showed that SCT has improved the survival rate and reduced the relapse rate of HL in young patients in recent years. Some background While initial treatment is...
Read MoreHow effective is BV-DHAP chemotherapy to treat patients with relapsed or refractory Hodgkin lymphoma?
In a nutshell This study examined the effectiveness and safety of the chemotherapy combination BV-DHAP for patients with relapsed or refractory Hodgkin lymphoma (HL). The authors found that BV-DHAP was an effective and safe treatment to progress patients to high-dose chemotherapy and stem cell transplant. Some background During treatment, some...
Read MoreLong-term outcomes of daratumumab with lenalidomide and dexamethasone in relapsed or unresponsive multiple myeloma
In a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...
Read MoreSecond-line tyrosine kinase treatment in patients with chronic myeloid leukemia who have failed first-line treatment
In a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment. This study concluded that these patients have good outcomes with second-line TKI treatment. Some background Tyrosine kinase...
Read MoreReviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma
In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....
Read MoreHave outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?
In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...
Read MoreThe comparison of outcomes of two salvage therapies in patients with relapsed or unresponsive acute myeloid leukemia
In a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...
Read MoreThe effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials
In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...
Read MoreEvaluating BEB chemotherapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of BEB (busulfan, etoposide, bendamustine) chemotherapy for patients with non-Hodgkin’s lymphoma (NHL). This study found that BEB chemotherapy was effective and well-tolerated in these patients. Some background Autologous stem cell transplantation (ASCT) is a standard...
Read MoreEvaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy
In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...
Read More